These authors contributed equally to the work # These authors shared co-last authorship Methods Synthesis of Peptide-PMO Conjugates. Pip6a Ac-(RXRRBRRXRYQFLIRXRBRXRB)-CO OH was synthesized and conjugated to PMO as described previously (1). The PMO sequence targeting CUG expanded repeats (5′-CAGCAGCAGCAGCAGCAGCAG-3′) and PMO control reverse (5′-GACGACGACGACGACGACGAC-3′) were purchased from Gene Tools LLC.
Fluorescent in situ hybridization / immunofluorescence. Fluorescent in situ hybridization (FISH) experiments were done as previously described (6) using a Cy3-labeled 2′OMe (CAG)7 probe (Eurogentec) . For combined FISH-Immunofluorescence experiments, immunofluorescence staining was done after FISH last washing as described previously (7) with a rabbit polyclonal anti-MBNL1 antibody (gift from C. Thornton ; 1:2000) followed by a secondary Alexa Fluor 488-conjugated goat anti-rabbit (1:500, Life technologies) antibody. Single molecule FISH (smFISH) was performed as previously described (8) . Briefly cells are incubated with a mix a 24 human DMPK-specific DMA probes which are hybridized to a Cy3labelled universal FLAP oligonucleotide ( Supplementary table 6 ). Pictures were captured using an Olympus BX60 microscope and Metamorph software (Molecular Devices). Confocal images were taken with a Nikon Ti2 microscope equipped with a motorized stage and a Yokogawa CSU-W1 spinning disk head coupled with a Prime 95 sCMOS camera (Photometrics). Images were processed with Adobe Photoshop software. Automated counting of nuclei with foci, number of foci per nuclei and/or intensity of FISH signal was done using Fiji software and custom scripts.
RNA sequencing. Total RNA from gastrocnemius and quadriceps muscles of WT, HSA-LR and Pip6a-PMO-CAG7 treated mice were sent to the Wellcome Trust Centre for Human Genetics Sequencing Facility. After complete RNA quality control on each sample (quantification in duplicate and RNA6000 Nano LabChip analysis on Bioanalyzer from Agilent), libraries were generated from each sample using TruSeq Stranded mRNA Library Prep Kit (Illumina), where mRNA are isolated by polyA selection, and pooled together by multiplexing them using barcoded adapters. The pooled libraries were then sequenced on Illumina's HiSeq4000 sequencing system to obtain 150bp paired end reads. Sequence alignment was provided by the Sequencing Facility where the 150bp paired end reads were trimmed and mapped on Mus musculus mm10 reference genome using HISAT software (9) . Then, all bioinformatics and statistical analysis were performed using custom scripts. Differentially expressed splicing events (exon_bin) between WT, HSA-LR and Pip6a-PMO-CAG7 samples were identified using DEXSeq software(10) by (i) identifying all possible exon_bins from mm10 Gencode annotation (M12 release) and estimating exon_bin counts for each sample with the provided python scripts (ii) normalization and (iii) differential exon usage tests to quantify log2 fold changes between the different conditions and their associated p-values. Differential gene expression was computed using DESeq2 software (11) from gene counts generated by FeatureCounts tool (12) . Differentially expressed exon_bins or genes were assessed when the log2 fold change was greater than 2 and the adjusted p-value for multiple comparison above 0.1. Figure 8 : Pip6a-PMO corrects DM1-specific molecular symptoms in transdifferentiated muscle cells. Four days trans-differentiated immortalized DM1 fibroblasts (1300 CTG repeats) are treated with Pip6a-PMO-CAG7 (Pip6a-PMO) at 1 µM and analyzed after 24h. A) FISH (CAG probe, red) /immuno-fluorescence (MBNL1, green) on DM1 or WT differentiated cells treated with Pip6a-PMO (Scale bar: 10 µm). B) Quantification of mean number of foci per nucleus in treated DM1 differentiated cells (n=3; >300 nucleus per n). C) Quantification of splicing corrections, using RT-PCR, induced by Pip6a-PMO treatment in immortalized DM1 trans-differentiated muscle cells (n=5). Data are expressed as mean +/-SEM. Statistics: B, C, *, P<0.05 ; **, P<0.01; ***, P<0.001 ; ns: non-significant. Supplementary figure 9: Effect of Pip6a-PMO on alternative splicing profiles is specific to DM1 cells and CAG antisense sequence. A) Quantification of splicing changes of LDB3, MBNL1, SOS1, DMD transcripts in 4 days differentiated immortalized DM1 (2600 CTG repeats) myoblasts treated with Pip6a-PMO-Control (Pip6a-ctrl) at 1 µM and analyzed after 24 h (n=4). B) Quantification of splicing changes of LDB3, MBNL1, SOS1, DMD transcripts in 4 days differentiated immortalized WT myoblasts treated with Pip6a-PMO-CAG7 (Pip6a-PMO) at 1 µM and analyzed after 24 h (n=4). C) Quantification of splicing changes of LDB3, MBNL1, SOS1, DMD transcripts in 4 days differentiated immortalized DM1 (2600 CTG repeats) myoblasts treated with unconjugated PMO-CAG (PMO) at 1 µM and analyzed after 24 h (n=3). Data are expressed as mean +/-SEM. Statistics: One-way ANOVA with Newman-Keuls post-test; ns: nonsignificant.
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